Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Sees Large Increase in Short Interest

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) was the recipient of a significant increase in short interest in November. As of November 30th, there was short interest totalling 22,800 shares, an increase of 31.0% from the November 15th total of 17,400 shares. Based on an average daily trading volume, of 2,580,000 shares, the short-interest ratio is currently 0.0 days. Currently, 1.4% of the shares of the stock are sold short.

Galmed Pharmaceuticals Stock Performance

Shares of GLMD traded up $0.16 during midday trading on Friday, hitting $2.97. The company had a trading volume of 31,667 shares, compared to its average volume of 714,124. The company’s 50-day simple moving average is $3.32 and its 200-day simple moving average is $3.96. The firm has a market capitalization of $1.90 million, a P/E ratio of -0.18 and a beta of 0.75. Galmed Pharmaceuticals has a 1 year low of $2.56 and a 1 year high of $23.80.

Analysts Set New Price Targets

Separately, StockNews.com initiated coverage on shares of Galmed Pharmaceuticals in a research note on Wednesday, October 9th. They set a “sell” rating on the stock.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.